In a report released today, Robert Driscoll from Wedbush reiterated a Buy rating on Arcus Biosciences (RCUS – Research Report), with a price target of $30.00. The company’s shares closed yesterday at $15.26.
According to TipRanks, Driscoll is a 4-star analyst with an average return of 8.7% and a 43.58% success rate. Driscoll covers the Healthcare sector, focusing on stocks such as Alpine Immune Sciences, Arvinas Holding Company, and CytomX Therapeutics.
Arcus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $41.00, which is a 168.68% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $35.00 price target.
RCUS market cap is currently $1.39B and has a P/E ratio of -3.68.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCUS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcus Biosciences (RCUS) Company Description:
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Read More on RCUS:
